Literature DB >> 12493358

Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder.

Linda Cardozo1, Dudley Robinson.   

Abstract

The term overactive bladder (OAB) is used to describe the symptoms of urinary frequency and urgency with or without urge incontinence. Commonly reported symptoms are nocturia, urgency, frequency, and urge incontinence. However, some of these symptoms may be because of other lower urinary tract conditions or may simply represent a variant of normal physiologic function. Consequently, special considerations need to be made when diagnosing OAB in women. In women of all ages, lower urinary tract infection is the most common cause of irritative urinary symptoms, and midstream urine microscopy and culture should be performed. A chronic urinary residual secondary to voiding difficulties may also result in symptoms of frequency and overflow incontinence and may be diagnosed using a postmicturition ultrasound scan. In premenopausal women, pregnancy should also be excluded. In postmenopausal women, urogenital atrophy can cause irritative symptoms that may be improved with hormone replacement therapy. Vaginal administration has been shown to be most effective and may be used to supplement systemic replacement therapy. In addition, estrogen replacement may be beneficial in the management of OAB as an adjunct to anticholinergic therapy. When investigating elderly women with OAB, special consideration should be given to comorbidities, such as constipation and fecal impaction, mobility problems, and the loss of independence. Concomitant medication, such as diuretics and alpha-adrenergic blockers, should also be noted and the need for therapy reviewed. In conclusion, OAB is a subjective diagnosis that should only be made when other lower urinary tract conditions have been excluded.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12493358     DOI: 10.1016/s0090-4295(02)01799-5

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

Review 1.  Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011.

Authors:  Anna P Malykhina; Jean-Jacques Wyndaele; Karl-Erik Andersson; Stefan De Wachter; Roger R Dmochowski
Journal:  Neurourol Urodyn       Date:  2012-02-29       Impact factor: 2.696

2.  Hormone replacement therapy has no routine role in the management of postmenopausal voiding dysfunction.

Authors:  Lesley K Carr
Journal:  Can Urol Assoc J       Date:  2009-04       Impact factor: 1.862

Review 3.  Overactive bladder in the elderly: a guide to pharmacological management.

Authors:  David R Staskin
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  Does central sensitization help explain idiopathic overactive bladder?

Authors:  W Stuart Reynolds; Roger Dmochowski; Alan Wein; Stephen Bruehl
Journal:  Nat Rev Urol       Date:  2016-06-01       Impact factor: 14.432

5.  Factors associated with urinary incontinence in middle-aged women: a population-based household survey.

Authors:  Cássia Raquel Teatin Juliato; Luiz F Baccaro; Adriana O Pedro; José R E Gabiatti; Jeffrey F Lui-Filho; Lucia Costa-Paiva
Journal:  Int Urogynecol J       Date:  2016-09-17       Impact factor: 2.894

6.  Influence of Menopausal Status on the Symptom Experience of Women Before Breast Cancer Surgery.

Authors:  Melissa Mazor; Janine K Cataldo; Kathryn Lee; Anand Dhruva; Steven M Paul; Betty J Smoot; Laura B Dunn; Jon D Levine; Judy Mastick; Yvette P Conley; Christine Miaskowski
Journal:  Cancer Nurs       Date:  2018 Jul/Aug       Impact factor: 2.592

Review 7.  Pharmacotherapy for nocturia in the elderly patient.

Authors:  Ragnar Asplund
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

8.  Bladder Symptoms in the Early Menopausal Transition.

Authors:  Holly J Jones; Alison J Huang; Leslee L Subak; Jeanette S Brown; Kathryn A Lee
Journal:  J Womens Health (Larchmt)       Date:  2016-01-07       Impact factor: 2.681

Review 9.  Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life.

Authors:  Marius Jan van der Mooren; Peter Kenemans
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Menopause hormonal therapy from the urologist's perspective.

Authors:  Deborah J Lightner
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.